Prasad S. Adusumilli: Publications


Gross DJ, Chintala NK, Vaghjiani RG, Grosser R, Tan KS, Li X, Choe J, Li Y, Aly RG, Emoto K, Hua Z, Dux J, Cheema W, Bott MJ, Travis WD, Isbell JM, Li BT, Jones DR, Adusumilli PS*. Tumor and Tumor-Associated Macrophage PD-L1 Expression is Associated with Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. J Thorac Oncol. 2022;17(1):89-102. [PMID: 34634452 ]

Adusumilli PS, Zauderer M, Riviere I, …Jones DR, Sadelain M. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD1 agent pembrolizumab. Cancer Discovery 2021. [PMID: 34266984]

Grosser R, Cherkassky L, Chintala NK, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471-82 [PMID: 31715131]

Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44. [PMID: 27454297]

Morello A, Sadelain M, Adusumilli PS. Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov. 2016;6(2):133-46. [PMID:26503962]

Kadota K, Nitadori JI, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD. Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol. 2015; 10(5):806-814. [PMID: 25378643]

Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151. [PMID: 25378643]

Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, Rusch VW, Travis WD, Adusumilli PS. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst. 2013;105(16):1212-20. [PMID:23926067]

Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis W, Sadelain M, Adusumilli PS. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor IL-12R & IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31(4):490-98. [PMID: 23269987]